Drugs / Nezulcitinib
Nezulcitinib
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05091723 | Oct → Nov 2021 | acute lung injury | Theravance Biopharma | Completed | No outcome recorded |
| Phase 1 | NCT04350736 | Apr → Jun 2020 | acute lung injury | Theravance Biopharma | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT04402866 | Jun 2020 → Apr 2021 | acute lung injury | Theravance Biopharma | Completed | Missed primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-02-23 | Theravance Biopharma | Results Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update theravance.com ↗
The results show that inhaled administration of nebulized TD-0903, once daily over seven days, was generally well-tolerated and showed a numerical trend towards improved clinical status, reduced hospital stay and fewer deaths compared to placebo during a 28-day observation period. |
All press releases naming this drug 4 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | nezulcitinib | “The inhaled lung-selective pan-Janus kinase inhibitor nezulcitinib had favourable safety and potential efficacy signals in part 1 of a phase 2 trial in patients with severe...” PMID 37460276 ↗ Jul 2023 |
| Known as | TD-0903 | “single inhaled dose of nezulcitinib (TD-0903)” NCT05091723 ↗ |
| Known as | THRX-136377 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802163 ↗ |
| Action | Inhibit | “pan-Janus kinase inhibitor” NCT04402866 ↗ |
| Modality | Small molecule | — CHEMBL4802163 ↗ |
| Route | Inhaled | “Study drug to be administered by inhalation” NCT04350736 ↗ |